[68Ga]Ga-NY104 PET/CT and [18F]FDG PET/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, single-center, single-arm, comparative imaging trial
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07755-5 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Xinchun Yan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College …. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE: This study aimed to compare the diagnostic performance of CAIX-targeted [68Ga]Ga-NY104 PET/CT versus standard [18F]FDG PET/CT in metastatic clear cell renal cell carcinoma (ccRCC). METHODS: In this prospective single-center trial (NYCRM), 45 patients with histologically confirmed metastatic ccRCC underwent paired [68Ga]Ga-NY104 and [18F]FDG PET/CT scans within 7 days. Lesions were evaluated using a standardized composite reference (histopathology, imaging, and follow-up). Primary endpoints were lesion- and region-level sensitivity/specificity; secondary endpoints included SUVmax, tumor-to-background ratios (TBR), and clinical management impact. RESULTS: Among 682 analyzed lesions, [68Ga]Ga-NY104 demonstrated superior sensitivity (94.4% vs. 78.2%, P < 0.001) and specificity (98.9% vs. 5.5%, P < 0.001) compared to [18F]FDG. Region-level analysis confirmed these findings (sensitivity: 97.0% vs. 82.2%; specificity: 97.5% vs. 10.0%). [68Ga]Ga-NY104 showed higher ccRCC lesion uptake (SUVmax: 12.4 ± 11.8 vs. 7.5 ± 10.7; TBR: 15.3 ± 14.6 vs. 4.7 ± 5.5, both P < 0.001) and lower non-ccRCC uptake (P < 0.001). Notably, [68Ga]Ga-NY104 identified 47 additional metastatic regions in 53% of patients and altered clinical management in 24% (11/45), including treatment intent or modality changes. CONCLUSION: This prospective head-to-head comparison between [68Ga]Ga-NY104 and [18F]FDG PET/CT in 45 patients with metastatic ccRCC shows superior sensitivity and specificity with [68Ga]Ga-NY104 PETCT than with [18F]FDG. It indicates that CAIX-targeting PET should be the PET tracer of choice over [18F]FDG in restaging ccRCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical…
- Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
- Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
- Department of Radiation Therapy, Peking University First Hospital, Beijing, China.
ORCID-Profile: Wenjia Zhu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yan, X., Li, X., Zheng, G., Ma, M., Liu, M., Wang, J., Zhang, Y., Ba, Y., Gao, X., Zhu, W., & Huo, L. (2026). [68Ga]Ga-NY104 PET/CT and [18F]FDG PET/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, single-center, single-arm, comparative imaging trial. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07755-5
Vancouver
Yan X, Li X, Zheng G, Ma M, Liu M, Wang J, et al. [68Ga]Ga-NY104 PET/CT and [18F]FDG PET/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, single-center, single-arm, comparative imaging trial. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07755-5
BibTeX
@article{Yan2026,
author = {Yan, Xinchun and Li, Xiaoyuan and Zheng, Guoyang and Ma, Mingwei and Liu, Meixi and Wang, Jingnan and Zhang, Yushi and Ba, Yi and Gao, Xianshu and Zhu, Wenjia and Huo, Li},
title = {[68Ga]Ga-NY104 PET/CT and [18F]FDG PET/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, single-center, single-arm, comparative imaging trial},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07755-5}
}
EUVIMED